Varun R Kshettry1, Quinn T Ostrom1, Carol Kruchko1, Ossama Al-Mefty1, Gene H Barnett1, Jill S Barnholtz-Sloan1. 1. Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio (V.R.K., G.H.B.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., C.K., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., C.K., J.S.B.-S.); Department of Neurosurgery, Brigham and Women's Hospital, Harvard School of Medicine, Boston, Massachusetts (O.A.-M.); Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio (G.H.B.).
Abstract
BACKGROUND: Because World Health Organization (WHO) grades II and III meningiomas are relatively uncommon, there is limited literature on the descriptive epidemiology of these tumors, and the existing literature predates the 2000 WHO classification revisions. Our purpose was to provide a modern, population-based study of the descriptive epidemiology of WHO II and III meningiomas in the United States. METHODS: The Central Brain Tumor Registry of the United States (CBTRUS) was queried for intracranial meningiomas categorized by WHO grade for the 2004--2010 study period. Age-adjusted incidence (95% confidence interval in parentheses) per 100,000 population was calculated by age, sex, race, and ethnicity. Annual percent change (APC) was calculated using Joinpoint. RESULTS: From 2004 to 2010, the incidence of WHO II intracranial meningiomas increased from 0.28 (95% CI, 0.27--0.29) to 0.30 (95% CI, 0.28-0.32), representing an APC of 3.6% (95%CI, 0.8%-6.5%). Conversely, from 2000-2010, the incidence of WHO III meningiomas decreased from 0.13 (95% CI, 0.11-0.14) to 0.06 (95%CI, 0.06-0.07), representing an APC of -5.4% (95% CI, -6.8% to -4.0%). From 2004 to 2010, the overall proportion of WHO I, II, and III intracranial meningiomas was 94.6%, 4.2%, and 1.2%, respectively. For WHO II/III meningiomas, females in the 35-64 year age group had a higher incidence than males in the same age group, whereas males in the ≥ 75 year age group ≥ had a higher incidence. Black and Asian Pacific Islander races were both associated with the highest incidence of WHO II/III meningiomas. Hispanic ethnicity was not associated with any difference in incidence. CONCLUSION: This study presents the most comprehensive evaluation of the modern descriptive epidemiology of WHO II and III meningiomas. Temporal trends likely reflect the 2000 WHO histological criteria revisions.
BACKGROUND: Because World Health Organization (WHO) grades II and III meningiomas are relatively uncommon, there is limited literature on the descriptive epidemiology of these tumors, and the existing literature predates the 2000 WHO classification revisions. Our purpose was to provide a modern, population-based study of the descriptive epidemiology of WHO II and III meningiomas in the United States. METHODS: The Central Brain Tumor Registry of the United States (CBTRUS) was queried for intracranial meningiomas categorized by WHO grade for the 2004--2010 study period. Age-adjusted incidence (95% confidence interval in parentheses) per 100,000 population was calculated by age, sex, race, and ethnicity. Annual percent change (APC) was calculated using Joinpoint. RESULTS: From 2004 to 2010, the incidence of WHO II intracranial meningiomas increased from 0.28 (95% CI, 0.27--0.29) to 0.30 (95% CI, 0.28-0.32), representing an APC of 3.6% (95%CI, 0.8%-6.5%). Conversely, from 2000-2010, the incidence of WHO III meningiomas decreased from 0.13 (95% CI, 0.11-0.14) to 0.06 (95%CI, 0.06-0.07), representing an APC of -5.4% (95% CI, -6.8% to -4.0%). From 2004 to 2010, the overall proportion of WHO I, II, and III intracranial meningiomas was 94.6%, 4.2%, and 1.2%, respectively. For WHO II/III meningiomas, females in the 35-64 year age group had a higher incidence than males in the same age group, whereas males in the ≥ 75 year age group ≥ had a higher incidence. Black and Asian Pacific Islander races were both associated with the highest incidence of WHO II/III meningiomas. Hispanic ethnicity was not associated with any difference in incidence. CONCLUSION: This study presents the most comprehensive evaluation of the modern descriptive epidemiology of WHO II and III meningiomas. Temporal trends likely reflect the 2000 WHO histological criteria revisions.
Authors: Meike W Vernooij; M Arfan Ikram; Hervé L Tanghe; Arnaud J P E Vincent; Albert Hofman; Gabriel P Krestin; Wiro J Niessen; Monique M B Breteler; Aad van der Lugt Journal: N Engl J Med Date: 2007-11-01 Impact factor: 91.245
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Haley Gittleman; David J Cote; Quinn T Ostrom; Carol Kruchko; Timothy R Smith; Elizabeth B Claus; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2017-06-30 Impact factor: 4.130
Authors: Georg Alexander Gihr; Diana Horvath-Rizea; Nikita Garnov; Patricia Kohlhof-Meinecke; Oliver Ganslandt; Hans Henkes; Hans Jonas Meyer; Karl-Titus Hoffmann; Alexey Surov; Stefan Schob Journal: Mol Imaging Biol Date: 2018-08 Impact factor: 3.488
Authors: Pranay Soni; Mark A Davison; Jianning Shao; Arbaz Momin; Diana Lopez; Lilyana Angelov; Gene H Barnett; Joung H Lee; Alireza M Mohammadi; Varun R Kshettry; Pablo F Recinos Journal: J Neurooncol Date: 2020-11-17 Impact factor: 4.130